Regeneron [REGN] vs Alnylam [ALNY] Detailed Stock Comparison

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

Alnylam Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Regeneron Pharmaceuticals, Inc. wins in 16 metrics, Alnylam Pharmaceuticals Inc. wins in 4 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals Inc. Better
P/E Ratio (TTM) 18.00 132.73 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 2.45 52.09 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 9.51 376.19 Regeneron Pharmaceuticals, Inc.
PEG Ratio -4.80 22.00 Alnylam Pharmaceuticals Inc.
EV/EBITDA 16.72 74.03 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 31.41% 8.45% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 23.13% 12.01% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) 23.13% 12.01% Regeneron Pharmaceuticals, Inc.
Return on Equity 14.86% 73.28% Alnylam Pharmaceuticals Inc.
Return on Assets (TTM) 5.91% 6.81% Alnylam Pharmaceuticals Inc.
Free Cash Flow (TTM) $3.77B $465.38M Regeneron Pharmaceuticals, Inc.
Dividend Yield 0.59% N/A N/A
1-Year Return 15.66% -8.16% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 5.50 11.16 Regeneron Pharmaceuticals, Inc.
Enterprise Value $70.98B $41.25B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 4.95 11.11 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 84.95% 75.60% Regeneron Pharmaceuticals, Inc.
Revenue per Share (TTM) $137 $28 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $41.48 $2.34 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.40 0.38 Alnylam Pharmaceuticals Inc.
Short % of Float 2.55% 5.05% Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

REGN
ALNY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%
Alnylam Pharmaceuticals Inc.1.75%-1.49%0.29%-9.76%-26.49%-28.08%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%
Alnylam Pharmaceuticals Inc.-8.16%40.32%59.90%405.36%3,032.34%1,907.45%

Performance & Financial Health Analysis: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals Inc.

MetricREGNALNY
Market Information
Market Cap i$80.98B$41.87B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i642,4951,075,369
90 Day Avg. Volume i617,7651,141,756
Last Close$614.98$287.80
52 Week Range$503.25 - $821.11$281.36 - $495.55
% from 52W High-25.10%-41.92%
All-Time High$1,211.20 (Aug 26, 2024)$495.55 (Oct 20, 2025)
% from All-Time High-49.23%-41.92%
Growth Metrics
Quarterly Revenue Growth0.03%0.85%
Quarterly Earnings Growth-0.08%0.85%
Financial Health
Profit Margin (TTM) i0.31%0.08%
Operating Margin (TTM) i0.23%0.12%
Return on Equity (TTM) i0.15%0.73%
Debt to Equity (MRQ) i9.51376.19
Cash & Liquidity
Book Value per Share (MRQ)$304.65$5.96
Cash per Share (MRQ)$83.86$21.93
Operating Cash Flow (TTM) i$4.98B$524.08M
Levered Free Cash Flow (TTM) i$3.26B$128.79M
Dividends
Last 12-Month Dividend Yield i0.59%N/A
Last 12-Month Dividend i$4.46N/A

Valuation & Enterprise Metrics Analysis: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals Inc.

MetricREGN (Apr 24, 2026)ALNY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i18.00132.73
Forward P/E i14.2122.00
PEG Ratio i-4.8022.00
Price to Sales (TTM) i5.5011.16
Price to Book (MRQ) i2.4552.09
Market Capitalization
Market Capitalization i$80.98B$41.87B
Enterprise Value i$70.98B$41.25B
Enterprise Value Metrics
Enterprise to Revenue i4.9511.11
Enterprise to EBITDA i16.7274.03
Risk & Other Metrics
Beta i0.400.38
Book Value per Share (MRQ) i$304.65$5.96

Financial Statements Comparison: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricREGN (2025)ALNY (2025)
Revenue/Sales i14.34B3.71B
Cost of Goods Sold i2.10B681.87M
COGS % of Revenue i14.6%18.4%
Gross Profit i12.24B3.03B
Gross Margin i85.4%81.6%
Research & Development i5.85B1.32B
Operating Income (EBIT) i3.70B501.58M
Operating Margin i25.8%13.5%
EBITDA i5.00B676.22M
EBITDA Margin i34.8%18.2%
Pre-Tax Income i5.23B323.15M
Pre-Tax Income % of Revenue i36.5%8.7%
Income Tax i725.80M9.41M
Income Tax % of Revenue i5.1%0.3%
Net Income (Profit) i4.50B313.75M
Profit Margin i31.4%8.4%

Balance Sheet & Liquidity Metrics

MetricREGN (2025)ALNY (2025)
Cash & Equivalents i3.12B1.66B
Total Current Assets i18.02B4.05B
Total Current Assets % of Revenue i125.7%109.1%
Total Current Liabilities i4.37B1.47B
Total Current Liabilities % of Revenue i30.5%39.5%
Long-Term Debt i2.71B1.23B
Long-Term Debt % of Revenue i18.9%33.2%
Total Shareholders Equity i31.26B789.18M
Retained Earnings i35.80B-6.70B
Retained Earnings % of Revenue i249.6%-180.5%
Property, Plant & Equipment i1.54B384.79M

Cash Flow Statement Comparison

MetricREGN (2025)ALNY (2025)
Operating Cash Flow i6.30B639.50M
Operating Cash Flow % of Revenue i43.9%17.2%
Capital Expenditures i0-58.70M
Free Cash Flow i3.77B465.38M
FCF Margin i26.3%12.5%
Debt Repayment iN/A-1.19B
Common Stock Repurchase i-3.97BN/A

Short Interest & Institutional Ownership Analysis

MetricREGNALNY
Shares Short i2.55M5.06M
Short Ratio i4.464.49
Short % of Float i2.55%5.05%
Shares Outstanding i105.72M132.38M
Float Shares i98.55M132.07M
% Held by Insiders i1.98%0.19%
% Held by Institutions i91.08%101.05%
% Held by Public i6.94%-1.24%

Dividend Analysis & Yield Comparison: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals Inc.

MetricREGNALNY
Last 12-Month Dividend i$4.46N/A
Last 12-Month Dividend Yield i0.59%N/A
3-Year Avg Annual Dividend i$1.49N/A
3-Year Avg Dividend Yield i0.13%N/A
3-Year Total Dividends i$4.46N/A
Ex-Dividend DateFeb 20, 2026N/A